Inguinal hernia. Inguinal hernia
Conditions
Interventions
Intervention 1: BD,(Bupivacaine, Dexmedetomidine(Dexmedetomidine is from Origin Orion Pharma ,Germany) group 1 microgram per kilogram Dexmedetomidine 0.2 mg/ kg Bupivacaine 5% will be injected by a su
Treatment - Drugs
BD,(Bupivacaine, Dexmedetomidine(Dexmedetomidine is from Origin Orion Pharma ,Germany) group 1 microgram per kilogram Dexmedetomidine 0.2 mg/ kg Bupivacaine 5% will be injected by a surgeon in the inc
in (BO) group 0.5 mg/ kg Bupivacaine 5% and 1 ml normal saline will be injected by a surgeon in the incision site.
Sponsors
Vice Chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Months to 6 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients between the range of 6 months to 6 years old; (ASA I); patients who have surgery for unilateral inguinal hernia. Exclusion criteria: A history of bleeding disorders, allergies to Dexmedetomidine and bupivacaine; developmental delay; upper respiratory tract infection, congenital heart disease, liver and kidney failure, neurological disease, mental retardation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-operative pain. Timepoint: children's and infant's postoperative pain scale (CHIPPS). Method of measurement: Immediately after arriving in recovery, 1 hour, 2 hours, 3 hours and 4 hours after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sedation. Timepoint: Immediately after arriving in recovery, 1 hour, 2 hours, 3 hours and 4 hours after surgery. Method of measurement: Sedation score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAnahita Pourali
Shiraz University of Medical Sciences
Outcome results
None listed